|View printer-friendly version|
|October 01, 2001 11:39 a.m.|
|Teva's Copaxone® Shown to Reduce "Black Holes" in the Brain|
KANSAS City, Mo. and Jerusalem, Israel, October 1, 2001 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that a study published in the August issue of Neurology showed that COPAXONE® (glatiramer acetate for injection) reduced by 50% the percentage of permanent "black holes" that developed in patients with relapsing-remitting multiple sclerosis. Black holes are lesions MS can cause in the brain, and these lesions, if permanent, represent areas where the most severe and irreversible brain tissue damage has occurred.